The Journal for Nurse Practitioners
Volume 5, Issue 3 , Pages 176-184 , March 2009

Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review

  • Joyce Yu-Chia Lee

      Affiliations

    • All authors are employed in the Department of Pharmacy at the National University of Singapore.
    • A board-certified pharmacotherapy specialist, Joyce Yu-Chia Lee, PharmD, BCPS, is an assistant professor in the department and a clinical pharmacist at National Healthcare Group Polyclinics.
    • ,
  • Tan Miao Ling Ferlyn

      Affiliations

    • All authors are employed in the Department of Pharmacy at the National University of Singapore.
    • Tan Miao Ling Ferlyn is a preregistration community pharmacist at Guardian Health and Beauty Pharmacy.
    • ,
  • Alexandre Chan

      Affiliations

    • All authors are employed in the Department of Pharmacy at the National University of Singapore.
    • A board-certified pharmacotherapy specialist and oncology pharmacist, Alexandre Chan, PharmD, BCPS, BCOP, is an assistant professor in the department and a clinical pharmacist at the National Cancer Centre Singapore.

References 

  1. GlaxoSmithKline. Avandia (rosiglitazone) package insert. Research Triangle Park, NC; November 2007.
  2. Nathan DM , Buse JB , Davidson MB , et al.   Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes . Diabetes Care . 2007;31(1):173–175
  3. Zinman B . PPAR-g agonists in type 2 diabetes: how far have we come in preventing the inevitable? A review of the metabolic effects of rosiglitazone . Diabetes Obes Metab . 2001;3(Suppl 1):S34–S43
  4. Food and Drug Administration  . MedWatch-2007 Safety Information Alerts . Available at: www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm Accessed September 7, 2008.
  5. Nissen SE , Wolski K . Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . N Eng J Med . 2007;356(24):2457–2471 Erratum in: N Engl J Med. 2007;357(1):100.
  6. Home PD , Phil D , Pocock SJ , et al.   Rosiglitazone evaluated for cardiovascular outcomes – An interim analysis . N Engl J Med . 2005;357(1):28–38
  7. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Investigators  . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial . Lancet . 2006;368(9541):1096–1105 Erratum in: Lancet. 2006;368(9549):1770.
  8. Kahn SE , Haffner SM , Heise MA , et al.   Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy . N Engl J Med . 2006;355:2427–2443 Erratum in: N Engl J Med . 2007;356(13):1387–1388
  9. Gilling L , Suwattee P , DeSouza C , Asnani S , Fonseca V . Effects of the thiazolidinediones on cardiovascular risk factors . Am J Cardiovasc Drugs . 2002;2(3):149–156
  10. Krauss RM . Lipids and lipoproteins in patients with type 2 diabetes . Diabetes Care . 2004;27(6):1496–1504
  11. Begg C , Cho M , Eastwood S , et al.   Improving the quality of reporting of randomized controlled trials: the CONSORT statement . JAMA . 1996;276(8):637–639
  12. Moher D , Schulz KF , Altman DG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials . Lancet . 2001;357(9263):1191–1194
  13. Baksi A , James RE , Zhou B , Nolan JJ . Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea . Acta Diabetol . 2004;41(2):63–69
  14. Dargie HJ , Hildebrandt PR , Riegger GAJ , et al.   A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients With New York Heart Association Functional Class I or II heart failure . J Am Coll Cardiol . 2007;49:1696–1704
  15. Davidson JA , McMorn SO , Waterhouse BR , Cobitz AR . A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy . Clin Ther . 2007;29(9):1900–1914
  16. Garber A , Klein E , Bruce S , Sankoh S , Mohideen P . Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy . Diabetes Obes Metab . 2006;8(2):156–163
  17. Hanefeld M , Patwardhan R , Jones NP . A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment if type 2 diabetes . Nutr Metab Cardiovasc Dis . 2007;17(1):13–23
  18. Lebovitz HE , Dole JF , Patwardhan R , Rappaport E , Freed MI . Rosiglitazone monotherapy is effective in patients with type 2 diabetes . J Clin Endocrinol Metab . 2001;86(1):280–288
  19. Phillips LS , Grunberger G , Miller E , et al.   A Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes . Diabetes Care . 2001;24(2):308–315 Erratum in: Diabetes Care. 2001;24(5):973.
  20. Raskin P , Rendell M , Riddle MC , et al.   A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes . Diabetes Care . 2001;24(7):1226–1232 Erratum in: Diabetes Care . 2001;24(12):2158–2159
  21. Raskin P , McGrill J , Saad MF , et al.   Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone . Diabet Med . 2004;21(4):329–335
  22. Rosenstock J , Danny S , Strange P , et al.   Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients . Diabetes Care . 2006;29(3):554–559
  23. Sutton MSJ , Rendell M , Dandona P , et al.   A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes . Diabetes Care . 2002;25(11):2058–2064
  24. Weissman P , Goldstein BJ , Rosenstock J , et al.   Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study . Curr Med Res Opin . 2005;21(12):2029–2035
  25. Wolffenbuttel BHR , Gomis R , Squatrito S , et al.   Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients . Diabet Med . 2000;17(1):40–47
  26. Home PD , Pocock SJ , Beck-Nielsen H , et al.   Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD): study design and protocol . Diabetologia . 2005;48:1726–1735
  27. Viberti G , Kahn SE , Greene DA , et al.   A Diabetes Outcome Progression Trial (ADOPT) . Diabetes Care . 2002;25:1737–1743
  28. Derosa G , Cicero AFG , D'Angelo A , et al.   Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial . Clin Ther . 2006;28(5):679–688 Erratum in: Clin Ther. 2006;28(9):1483.
  29. Derosa G , D'Angelo A , Ragonesi PD , et al.   Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin . Intern Med J . 2007;37(2):79–86
  30. Goldberg RB , Kendall DM , Deeg MA , et al.   A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia . Diabetes Care . 2005;28(7):1547–1554
  31. Khan MA , Peter JVS , Xue JL . A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone . Diabetes Care . 2002;25(4):708–711
  32. Hallsten K , Virtanen KA , Lonnqvist F , et al.   Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone . Diabet Med . 2004;21(12):1280–1287
  33. Miyazaki Y , Glass L , Triplitt C , et al.   Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients . Diabetologia . 2001;44(12):2210–2219
  34. Nolan JJ , Jones NP , Patwardhan R , Deacon LF . Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus . Diabet Med . 2000;17(4):287–294
  35. Patel J , Anderson RJ , Rappaport EB . Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study . Diabetes Obes Metab . 1999;1(3):165–172
  36. Raskin P , Rappaport EB , Cole ST , et al.   Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes . Diabetologia . 2000;43(3):278–284
  37. Aronoff S , Rosenblatt S , Braithwaite S , et al.   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes . Diabetes Care . 2000;23(11):1605–1611
  38. Miyazaki Y , Matsuda M , DeFronzo RA . Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes . Diabetes Care . 2002;25(3):517–523
  39. Rosenblatt S , Miskin B , Glazer NB , et al.   The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus . Coron Artery Dis . 2001;12(5):413–423
  40. Wallace TM , Levy JC , Matthews DR . An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study . Diabet Med . 2004;21(6):568–576
  41. Rennie D . CONSORT revised–Improving the reporting of randomized trials . JAMA . 2001;285(15):2006–2007
  42. Moher D , Jones A , Lepage L , for the CONSORT Group  . (in press). Use of CONSORT statement and quality of reports of randomized trials: a comparative before and after evaluation . JAMA . 2001;285(15):1992–1995
  43. Karalliedde J , Buckingham RE . Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies . Drug Saf . 2007;30(9):741–753
  44. Granberry MC , Hawkins JB , Franks AM . Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure . Am J Health Syst Pharm . 2007;64(9):931–936
  45. Krische D . Medicine cabinet. The glitazones: Proceed with caution . West J Med . 2000;173:54–57
  46. Buse JB , Tan MH , Prince MJ , Erickson PP . The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes . Diabetes Obes Metab . 2004;6(2):133–156
  47. Dwan K , Altman DG , Arnaiz JA , et al.   Systematic review of the empirical evidence of study publication bias and outcome reporting bias . PLoS ONE . 2008;3(8):e3081
  48. Green S . Systematic review and meta-analysis . Singapore Med J . 2005;46(6):270–274
  49. Dormandy JA , Charbonnel B , Eckland DJ , et al.   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial . Lancet . 2005;366(9493):1279–1289
  50. Erdmann E , Dormandy JA , Charbonnel B , et al.   The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study . J Am Coll Cardiol . 2007;49:1772–1780

 In compliance with national ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.

PII: S1555-4155(08)00480-7

doi: 10.1016/j.nurpra.2008.09.004

The Journal for Nurse Practitioners
Volume 5, Issue 3 , Pages 176-184 , March 2009

Article Tools